NCT03575611 2026-04-15
Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Suspended
Clinical Trials
68 trialsNCT05960578 2026-04-14
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
University of Washington
Phase 2 Active not recruiting
NCT06616155 2026-04-13
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 1/2 Recruiting
NCT07526545 2026-04-13
UPRISE
University of Michigan Rogel Cancer Center
Phase NA Not yet recruiting
NCT06661720 2026-04-07
STRIKE
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT07510334 2026-04-03
VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Mayo Clinic
Phase 2 Not yet recruiting
NCT07145177 2026-03-23
177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 1 Recruiting
NCT07468903 2026-03-19
Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer
Jonsson Comprehensive Cancer Center
Phase NA Not yet recruiting
NCT05435495 2026-03-18
Mechanisms of Resistance to PSMA Radioligand Therapy
University of California, San Francisco
Recruiting
NCT05269381 2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2 Recruiting
NCT04947254 2026-02-19
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06305598 2026-02-19
Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
Roswell Park Cancer Institute
Phase 1 Recruiting
NCT05521698 2026-02-17
Study to Determine Possible Effects of Apalutamide, Compared to Placebo, on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer
University of Wisconsin, Madison
Phase 1 Not yet recruiting
NCT06236139 2026-02-17
Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
Fred Hutchinson Cancer Center
Phase 1/2 Recruiting
NCT04754425 2026-02-06
Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05730712 2026-02-06
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
Mayo Clinic
Phase 2 Completed
NCT05775471 2026-02-05
Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT02312401 2026-01-29
Evaluation of Treatment Response Using Multiparametric MRI After Prostate Radiotherapy
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06145633 2026-01-28
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Fred Hutchinson Cancer Center
Phase 2 Recruiting
NCT07352748 2026-01-28
MOSAIC
Universita di Verona
Active not recruiting
NCT06039371 2026-01-14
Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
University of Washington
Phase 2 Recruiting
NCT02210117 2026-01-07
Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT06391034 2026-01-07
Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer
University of California, San Francisco
Phase 2 Recruiting
NCT06630325 2026-01-07
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT06626256 2025-12-24
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
City of Hope Medical Center
Phase 1 Withdrawn
NCT04989959 2025-12-04
[18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma
University of Texas Southwestern Medical Center
Phase 1 Recruiting
NCT05805371 2025-11-19
PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT07226544 2025-11-10
Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer
City of Hope Medical Center
Phase 2 Not yet recruiting
NCT05362032 2025-10-24
Feasibility of OmnEcoil System for Integrated Endorectal MRI and Transrectal MRI-Targeted Biopsy of the Prostate
OHSU Knight Cancer Institute
Phase NA Suspended
NCT06499870 2025-10-21
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
Northwestern University
Phase 2 Recruiting
NCT07218692 2025-10-20
RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy
City of Hope Medical Center
Phase 2 Not yet recruiting
NCT06528210 2025-09-23
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Withdrawn
NCT05438563 2025-09-09
MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate Cancer
Mayo Clinic
Phase NA Recruiting
NCT06866262 2025-09-09
Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial
University of Michigan Rogel Cancer Center
Phase 1/2 Recruiting
NCT06424275 2025-08-15
PRAISE-U
European Association of Urology Research Foundation
Enrolling by invitation
NCT02543905 2025-07-25
PROFILE
Institute of Cancer Research, United Kingdom
Recruiting
NCT03844399 2025-07-20
(3D) Ultrasound Imaging Liver and Kidney
Western University, Canada
Recruiting
NCT06942104 2025-07-18
Imaging of Solid Tumors Using 18F-TRX
University of California, San Francisco
Phase 1 Recruiting
NCT05304858 2025-04-25
Tumor Microenvironment Analysis of Prostate Cancer Metastasis
Columbia University
Recruiting
NCT06094842 2025-04-01
Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer
Fred Hutchinson Cancer Center
Phase 1 Withdrawn
NCT03473730 2025-01-30
Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Completed
NCT05228197 2025-01-22
IP6-CHAIROS
Imperial College London
Active not recruiting
NCT05655715 2024-10-16
CheckPRO
Herlev and Gentofte Hospital
Phase 2 Completed
NCT02555189 2024-05-13
Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression
Thomas Jefferson University
Phase 1/2 Completed
NCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT03225222 2023-09-07
MR-PROPER
Erasmus Medical Center
Completed
NCT05069584 2023-05-23
PERFECT
GCS Ramsay Santé pour l'Enseignement et la Recherche
Phase NA Completed
NCT05603351 2022-11-02
ProstaPilot
Masaryk Memorial Cancer Institute
Phase NA Unknown
NCT02901548 2022-07-29
Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT04247217 2022-05-26
PRIMUS
Maastricht Radiation Oncology
Completed